Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:2857738rdf:typepubmed:Citationlld:pubmed
pubmed-article:2857738lifeskim:mentionsumls-concept:C0030705lld:lifeskim
pubmed-article:2857738lifeskim:mentionsumls-concept:C1956346lld:lifeskim
pubmed-article:2857738lifeskim:mentionsumls-concept:C0042380lld:lifeskim
pubmed-article:2857738lifeskim:mentionsumls-concept:C1522318lld:lifeskim
pubmed-article:2857738lifeskim:mentionsumls-concept:C2003941lld:lifeskim
pubmed-article:2857738lifeskim:mentionsumls-concept:C0599946lld:lifeskim
pubmed-article:2857738lifeskim:mentionsumls-concept:C0332206lld:lifeskim
pubmed-article:2857738pubmed:issue4lld:pubmed
pubmed-article:2857738pubmed:dateCreated1985-4-25lld:pubmed
pubmed-article:2857738pubmed:abstractTextAlpha-adrenergic-mediated coronary vasoconstriction during stress such as cold pressor testing may contribute to myocardial ischemia by increasing coronary vascular resistance in patients with severe coronary artery disease. Nonselective alpha-receptor blockade with phentolamine abolishes both the peripheral and coronary vasoconstriction during cold pressor testing, but causes reflex tachycardia and increased inotropy. To determine the role of selective alpha 1-receptor blockade, the changes in coronary vascular resistance during cold pressor testing were measured in 18 patients with coronary artery disease before and after intravenous administration of 100 mg of trimazosin. Cold pressor testing was performed at a constant paced subanginal heart rate of 95 +/- 5 beats/min (+/- 1 SD). Before trimazosin, cold pressor testing increased mean arterial pressure by 9 +/- 4% (102 +/- 14 to 111 +/- 14 mm Hg, p less than 0.001) with no change in coronary sinus blood flow, but significantly increased coronary vascular resistance by 15 +/- 19% (1.02 +/- 0.46 to 1.15 +/- 0.57 units, p less than 0.05). Five minutes after trimazosin, cold pressor testing increased mean arterial pressure by 6 +/- 5% (p less than 0.001) with a marked attenuation of the increase in coronary vascular resistance (6 +/- 11%, p = NS), which was significantly less than before trimazosin (p less than 0.02). Trimazosin did not increase plasma norepinephrine concentration at rest, suggesting that in the dosage used trimazosin caused selective alpha 1-receptor blockade.(ABSTRACT TRUNCATED AT 250 WORDS)lld:pubmed
pubmed-article:2857738pubmed:granthttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2857738pubmed:languageenglld:pubmed
pubmed-article:2857738pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2857738pubmed:citationSubsetIMlld:pubmed
pubmed-article:2857738pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2857738pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2857738pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2857738pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2857738pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:2857738pubmed:statusMEDLINElld:pubmed
pubmed-article:2857738pubmed:monthAprlld:pubmed
pubmed-article:2857738pubmed:issn0735-1097lld:pubmed
pubmed-article:2857738pubmed:authorpubmed-author:MudgeG HGHJrlld:pubmed
pubmed-article:2857738pubmed:authorpubmed-author:BarryW HWHlld:pubmed
pubmed-article:2857738pubmed:authorpubmed-author:HorowitzJ DJDlld:pubmed
pubmed-article:2857738pubmed:authorpubmed-author:KernM JMJlld:pubmed
pubmed-article:2857738pubmed:authorpubmed-author:ColucciW SWSlld:pubmed
pubmed-article:2857738pubmed:authorpubmed-author:GanzPPlld:pubmed
pubmed-article:2857738pubmed:authorpubmed-author:GasparJJlld:pubmed
pubmed-article:2857738pubmed:authorpubmed-author:LorellB HBHlld:pubmed
pubmed-article:2857738pubmed:issnTypePrintlld:pubmed
pubmed-article:2857738pubmed:volume5lld:pubmed
pubmed-article:2857738pubmed:ownerNLMlld:pubmed
pubmed-article:2857738pubmed:authorsCompleteYlld:pubmed
pubmed-article:2857738pubmed:pagination840-6lld:pubmed
pubmed-article:2857738pubmed:dateRevised2008-11-21lld:pubmed
pubmed-article:2857738pubmed:meshHeadingpubmed-meshheading:2857738-...lld:pubmed
pubmed-article:2857738pubmed:meshHeadingpubmed-meshheading:2857738-...lld:pubmed
pubmed-article:2857738pubmed:meshHeadingpubmed-meshheading:2857738-...lld:pubmed
pubmed-article:2857738pubmed:meshHeadingpubmed-meshheading:2857738-...lld:pubmed
pubmed-article:2857738pubmed:meshHeadingpubmed-meshheading:2857738-...lld:pubmed
pubmed-article:2857738pubmed:meshHeadingpubmed-meshheading:2857738-...lld:pubmed
pubmed-article:2857738pubmed:meshHeadingpubmed-meshheading:2857738-...lld:pubmed
pubmed-article:2857738pubmed:meshHeadingpubmed-meshheading:2857738-...lld:pubmed
pubmed-article:2857738pubmed:meshHeadingpubmed-meshheading:2857738-...lld:pubmed
pubmed-article:2857738pubmed:meshHeadingpubmed-meshheading:2857738-...lld:pubmed
pubmed-article:2857738pubmed:meshHeadingpubmed-meshheading:2857738-...lld:pubmed
pubmed-article:2857738pubmed:meshHeadingpubmed-meshheading:2857738-...lld:pubmed
pubmed-article:2857738pubmed:meshHeadingpubmed-meshheading:2857738-...lld:pubmed
pubmed-article:2857738pubmed:meshHeadingpubmed-meshheading:2857738-...lld:pubmed
pubmed-article:2857738pubmed:meshHeadingpubmed-meshheading:2857738-...lld:pubmed
pubmed-article:2857738pubmed:meshHeadingpubmed-meshheading:2857738-...lld:pubmed
pubmed-article:2857738pubmed:meshHeadingpubmed-meshheading:2857738-...lld:pubmed
pubmed-article:2857738pubmed:year1985lld:pubmed
pubmed-article:2857738pubmed:articleTitleAttenuation of coronary vascular resistance by selective alpha 1-adrenergic blockade in patients with coronary artery disease.lld:pubmed
pubmed-article:2857738pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:2857738pubmed:publicationTypeResearch Support, U.S. Gov't, P.H.S.lld:pubmed
pubmed-article:2857738pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed